Issue 6/2017
Content (15 Articles)
Invited Commentary
Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?
Brady L Stein, Srdan Verstovsek
Invited Commentary
Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
Naveen Pemmaraju
Myelodysplastic Syndromes (M Savona, Section Editor)
Models of Prognostication in Chronic Myelomonocytic Leukemia
Francesco Onida
CART and Immunotherapy (M Ruella, Section Editor)
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
Nathan Singh, Junwei Shi, Carl H. June, Marco Ruella
Acute Myeloid Leukemias (H Erba, Section Editor)
Predicting Chemotherapy Resistance in AML
Cecilia C. S. Yeung, Jerald Radich
Acute Myeloid Leukemias (H Erba, Section Editor)
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
Brittany Knick Ragon, Courtney D. DiNardo
Acute Myeloid Leukemias (H Erba, Section Editor)
The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia
Francesco Buccisano, Christopher S. Hourigan, Roland B. Walter
Acute Myeloid Leukemias (H Erba, Section Editor)
Methods of Detection of Measurable Residual Disease in AML
Yi Zhou, Brent L. Wood
Acute Myeloid Leukemias (H Erba, Section Editor)
Diagnostic and Prognostic Utility of Fluorescence In situ Hybridization (FISH) Analysis in Acute Myeloid Leukemia
Patrick R. Gonzales, Fady M. Mikhail
Acute Myeloid Leukemias (H Erba, Section Editor)
Measurement of Residual Disease in Acute Myeloid Leukemia
Rahul S. Vedula, R. Coleman Lindsley
Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)
Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?
Aaron T. Gerds, Teresa Chan
Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)
Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN
Naveen Pemmaraju, Audun Utengen, Vikas Gupta, Michael A. Thompson, Andrew A. Lane
Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)
Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media—#MPNSM
Naveen Pemmaraju, Audun Utengen, Vikas Gupta, Jean-Jacques Kiladjian, Ruben Mesa, Michael A. Thompson
Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)
Using Social Media at National Meetings in Hematology—Optimal Use, Tips, Strategies, and Limitations
Aaron C. Logan
Myeloproliferative Neoplasms (B Stein, Section Editor)
Novel Therapies for Myelofibrosis
Kristen Pettit, Olatoyosi Odenike